Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GI Dynamics Goes Down Under To Fund First Endoscopic Treatment For Diabetes

This article was originally published in The Gray Sheet

Executive Summary

The Massachusetts-based developer of the EndoBarrier device is leveraging its presence on the Australian stock exchange to finance its drug-like clinical development changes.

You may also be interested in...



GI Dynamics Terminates Pivotal Endobarrier Trial Based On Safety Data

FDA and the company could not come up with a plan to continue the ENDO study for GI's device targeting obese patients with diabetes in response to higher-than-anticipated rates of liver infection. The company suggests, however, that development of the device will continue.

Obesity 2015: Less Invasive Options Will Drive Growth In Market Hungry For Solutions

Nearly half of the world’s adult population will be overweight or obese by 2030 and obesity is tied to more than 40 diseases. Enterprising companies are heeding the call with increasingly less invasive weight loss devices, while an amenable regulatory environment means the marketplace will welcome some of these innovations in 2015.

People Briefs: GI Dynamics CEO; Allergan CFO; HeartFlow Changes

New CEO for GI Dynamics. Allergan names Jim Hindman CFO. HeartFlow makes executive suite changes; Biogen Idec appoints new executive VP.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT032277

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel